Contraindications and interactions first, the heartburn claim last: a composite heart failure patient's licorice root capsules, examined in an NU434 Unit 7 supplement safety brief. Searches like "nu 434 unit 7 assignment example", "nu434 unit 7 sample" and "nu434 unit 7 example" land here.
What a finished NU434 Unit 7 supplement safety brief looks like
Two to three pages in a clinical brief format, headed by a boxed summary of the concern. The client profile is short: heart failure with reduced ejection fraction, furosemide and digoxin prescribed, and licorice root capsules bought for heartburn and taken for [six] weeks, the product's glycyrrhizin content not stated on its label. Page one lists contraindications, including hypertension, heart failure, kidney disease, low potassium and pregnancy, with a source for each. Interactions follow in a table: furosemide, where potassium loss adds up; digoxin, where low potassium raises the risk of toxicity; and the heart failure itself, since glycyrrhizin promotes sodium and fluid retention. A mechanism paragraph explains why: glycyrrhizin blocks an enzyme that normally keeps cortisol off the mineralocorticoid receptor. Deglycyrrhizinated products are noted as a separate case.
How a NU434 Unit 7 example is structured
Order is the argument, harm before benefit, and the brief says so in its opening line. The boxed summary names the single most important finding, a supplement that pulls potassium down in a patient whose medications already do. Contraindications come next as a list, each with its source, from NCCIH's licorice root summary and a licensed interaction database to the FDA's consumer warning on black licorice for adults 40 and older. The interaction table follows, one row per prescription, with a column stating the type of evidence: case reports, pharmacology or controlled study. Product quality receives a short section on unlabeled glycyrrhizin content and on deglycyrrhizinated forms. Claimed benefits appear only on the final page, briefly, with the limited evidence for heartburn relief stated plainly. A routing statement addressed to the cardiologist and pharmacist ends the brief.
The boxed concern
One sentence at the top states the risk in plain terms: a product that lowers potassium, taken by a patient on a diuretic and digoxin, with fluid retention added on top.
Contraindications before anything else
Hypertension, heart failure, kidney disease, hypokalemia and pregnancy are listed with sources, so a reader who stops after the first page still leaves with the essential information.
One row per prescription
Furosemide, digoxin and the heart failure diagnosis each get a row stating the concern, its mechanism and the kind of evidence behind it, from pharmacology to published case reports.
Glycyrrhizin, labeled or not
Many licorice products do not state glycyrrhizin content, and deglycyrrhizinated forms remove most of it. The brief explains why this label leaves the risk from this particular bottle unknowable.
Routed, not resolved
No one is told to stop or continue anything. The full product list goes to the cardiologist and pharmacist, with the potassium concern placed at the top of the page.
Where marks go in NU434 Unit 7
Supplement briefs are judged first on order and completeness. A document that opens with licorice's traditional uses and its soothing effect on the stomach, then mentions a caution near the end, has inverted what this unit usually asks, and a missed digoxin interaction in a heart failure scenario tends to outweigh everything else on the page. Rubrics frequently reward a mechanism explained in a sentence, since knowing why glycyrrhizin lowers potassium lets a reader predict interactions that are not listed. Scope is the other major criterion: advising the client to stop the capsules or adjust the diuretic belongs to the prescriber, and a brief that does so reads as practice outside nursing. Sources from retail sites, evidence types left unlabeled, and silence on product variability each cost further credit.
Get a NU434 Unit 7 example written to your instructions
Which product does the Unit 7 scenario involve, and what else is on the client's medication list? Paste both exactly as given, with the rubric. The brief leads with contraindications and interactions, labels its evidence, and routes every concern to a prescriber. A first sample costs nothing and lands inside 24-48h, built on your instructions.
NU434 Unit 7 questions, answered
Can the brief say the client should stop the supplement?
Not as an instruction. The brief can state that the combination raises a serious concern and that the prescriber and pharmacist should review it promptly, which communicates urgency without prescribing. Telling a client to stop a product, or to change a medication, belongs to the prescriber in most practice settings, and instructors in this course often treat that line as a scope test.
Why do the benefits come last?
Because the reader of a safety brief is deciding whether a product is safe for this person, and that question does not depend on whether it works. A benefit section placed first frames the risks as side notes, and many rubrics in this unit expect the reverse order. The sample still reports the heartburn evidence honestly, limited as it is, so the brief stays balanced.
Does deglycyrrhizinated licorice raise the same concerns?
Largely not, because processing removes most of the glycyrrhizin responsible for potassium loss and fluid retention. The brief mentions it to show that product form matters, not to recommend a switch, which would be the prescriber's call. If your scenario involves a product labeled DGL, the interaction table changes substantially, and the brief should say so explicitly.